title: Conventional vs concomitant boost radiotherapy with concurrent cisplatin in advanced head and neck cancer.
abstract: OBJECTIVE
  To compare outcome of concomitant boost therapy (CBT) with conventional radiotherapy with cisplatin as a radiosensitizer in advanced head and neck cancer.
  
  
  METHODS
  Prospective comparative study was undertaken. Patients were assigned alternately to ArmA (conventional arm) and ArmB (CBT arm), 30 in each arm and total 60 patients were enrolled.
  
  
  RESULTS
  Out of 30 patients in conventional Arm A, 13 had complete response (CR; 43.33%), 9 had partial response (PR; 30%), three patients (10%) had stable disease (SD), and five patients (16.66%) had progressive disease (PD). In arm B out of 30 patients, 18 patients (60%) had CR, five patients (16.66%) had partial response (PR), four patients (13.33%) showed SD, and three patients (10%) had PD. There was no statistically significant difference between the two arms for CR (P - value = 0.196).
  
  
  CONCLUSIONS
  CBT can be used as an alternative to conventional RT in advanced head and neck cancers which minimize the total duration and the workload can be reduced. The locoregional control with CBT is comparable with the response of conventional RT.
authors.affiliation: Department of Radiation Therapy and Oncology, Government Medical College and Hospital, Nagpur, Maharashtra, India.
authors.forename: Sushil Dashrath
authors.initials: SD
authors.lastname: Meshram
authors.forename: Krishna M
authors.initials: KM
authors.lastname: Kamble
authors.forename: Ashok K
authors.initials: AK
authors.lastname: Diwan
authors.forename: Vijay K
authors.initials: VK
authors.lastname: Mohobia
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D020266:Radiotherapy, Conformal; D015996:Survival Rate
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin